(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/204713 A1

(51) International Patent Classification:
A61P 31/14 (2006.01) *A61K 31/502* (2006.01)

(21) International Application Number:
PCT/EP2021/058774

(22) International Filing Date:
01 April 2021 (01.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/007,019 08 April 2020 (08.04.2020) US
63/109,393 04 November 2020 (04.11.2020) US

(71) Applicant: **BERGENBIO ASA** [NO/NO]; Jonas Lies Vei 91, 5009 Bergen (NO).

(72) Inventors: **LORENS, James Bradley**; c/o BerGenBio ASA, Jonas Lies Vei 91, 5009 Bergen (NO). **MAURY, Wendy**; c/o Department of Microbiology and Immunology, University of Iowa, Iowa City, Iowa (US).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

WO 2021/204713 A1

(54) Title: AXL INHIBITORS FOR ANTIVIRAL THERAPY




Figure 1

(57) Abstract: This disclosure relates to compostions and methods for preventing and treating a viral infection in a subject. In particular, the present disclosure provides compostions and methods of preventing or treating infection of a subject with a coronavirus such as the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) that causes the disease COVID-19.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*